US Patent 10059699 Tetrahydroquinoline derivatives as bromodomain inhibitors
Patent 10059699 was granted and assigned to GlaxoSmithKline on August, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+182 characters)
Article
Patent abstract
The present invention relates to specific novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy as bromodomain inhibitors.
Edits on 23 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100596990
Date of Patent
August 28, 2018
0Patent Application Number
155098940
Date Filed
September 9, 2015
0Patent Citations Received
Patent Primary Examiner
Edits on 23 Feb, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100596990
Date of Patent
August 28, 2018
0Patent Application Number
155098940
Date Filed
September 9, 2015
0Patent Primary Examiner
Edits on 21 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10059699 Tetrahydroquinoline derivatives as bromodomain inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10059699
Date of patent
August 28, 2018
Patent application number
15509894
Date Filed
September 9, 2015
Patent primary examiner
Find more entities like US Patent 10059699 Tetrahydroquinoline derivatives as bromodomain inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
